האיגוד הישראלי לרפואת משפחה
כעת 6751 ערכים
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
האיגוד הישראלי לרפואת משפחה
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
כעת 6751 ערכים
האיגוד הישראלי לרפואת משפחה

המלצות כוח המשימה הישראלי בנושא קידום בריאות ורפואה מונעת/ביבליוגרפיה מהדורת 2000

מתוך ויקירפואה
המלצות כוח המשימה הישראלי בנושא
קידום בריאות ורפואה מונעת
המלצות כוח המשימה.png
שם הפרק רשימה ביבליוגרפית
עורך מדעי פרופ' חוה טבנקין, ד"ר אמנון להד - איגוד רופאי המשפחה
מוציא לאור ההסתדרות הרפואית בישראל, האגף למדיניות רפואית, איגוד רופאי המשפחה בישראל
מועד הוצאה מהדורת 2013
מספר עמודים 249
 

ביבליוגרפיה

מהדורת 2000

  1. United States Preventive Services Task Force. Guide to clinical Preventive Service. Second Edition. Baltimore Md: Williams & Wilkins 1996. Update: www.preventiveservices.ahrq.gov
  2. Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventive Health care. Canada Communication group publishing 1998.
  3. Sox HC. Preventive Health Services in Adults. N Engl J Med 1994; 330: 1589-1595.
  4. Battista RN, Lawrence RS eds. Implementing preventive Services. Am J Prev Med 1988; 4 (supp 8).
  5. Bravrman P.A & Tarimo A. Screening in Primary health care-Setting priorites with limited resources. WHO Publication 1994.
  6. Prevention in Primary Care- Recommendations for promoting good-practice-CINDI 2000 Editied by Dobrossy, WHO Regional office for Europe Publication, 1994.
  7. Patterson C, Chambers LW. Preventive health care. Lancet. 1995; 345: 1611-15.
  8. שינויים בשיגרת החיסונים 2003 - הוראות משת הבהאות שירותי בריאות הציבור המח׳ לאפידמיולוגיה, ירושלים 2003.
  9. הנחיות משרד הבריאות בנושא מעקב גדילה והתפתחות ילדים עד גיל 5. שירותי בהאות הציבור משרד הבהאות 1995 + עדכונים.
  10. המלצות הועדה המייעצת לארגון רופאי הילדים ספט׳ 1992.
  11. Valman HB. A B C of One to Seven. Published by the BMJ publishing Group, 3rd edition 1993.
  12. Fixler DE. and Pernoch LW. Validity of mass blood pressure screening in children. Pediatrics 1983; 72: 459-463.
  13. Palti H. Blood Pressure assessment in children. Isr. J Med Sci 1987; 23: 785-787.
  14. Zadik M, Sthoper D and Blachar Y. Blood Pressure determinations in Israeli school children aged 5 to 14 years. Isr. J Med Sci 1987; 23: 798-8022.
  15. Task Force on Blood Pressure Control in Children, Pediatrics 1987; 79: 1-25.
  16. Baron AE, Freyer B and Fixler DE Longitudinal blood pressure in blacks, whites and Mexican
  17. Americans during adolescence and early adulthood. Am J Epdemiol 1986; 123: 809-8
  18. הנחיות משרד הבהאות בנושא מעקב נשים בהריון, שירותי בריאות הציבור 1995 + עדכונים.
  19. Ewigman B G, Grane J P, frigoletto FD, Lefevre ML et al. Efect of prenatal ultrasaund screening on perinatal outcome. RADIVS Group. N Engl J Med 1993; 329 (12): 821-7.
  20. Berkowitz R L. Should every pregnant woman undrgo ultrasongraphy? N Engl J Med 1993; 329: 874-875.
  21. Bernaschek G, Stuempflen L. Deutinger J. The value of sonographic diagnosis of fetal malformation: different results between indication based investigations. Prenat Diagn 1994; 14(9): 807-812.
  22. Bragonier JR, Bemis Heys RL. Cost effectiveness in the provision of primary health care services for women. Prim Care Update Ob/Gyn: 1994; 11(6): 245-248.
  23. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
  24. Pyorala K, De Backer G, Graham P, Poole-Wilson P, Wood D. On behalf of the European Task force. Prevention of coronary heart disease in clinical Practice. European Heart Journal. 1994; 15: 1300-1331.
  25. Carruthers SG et al. Report of the Canadian Hypertension Society Consensus Conference. Can Med Assoc J 1993; 149 (3): 289-291/149 (4): 409418; 149 (5): 575-584; 149 (6): 815-26.
  26. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
  27. Expert Panel on Detection, and Treatment of high Blood Cholesterol in Adults. Summary of the second report of the National Cholestrol Educatin Program (NCEP) Expert Panel. JAMA 1993; 269: 3015-23.
  28. Krumholz HM et al. Lack of association between cholesterol and coronary Heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272 (17) 1335-1341.
  29. Willett WC. Diet and health, What should we eat. Science 1994; 264: 532-537.
  30. NIH Consensus Development Panel on optimal calcium intake. JAMA 1994; 272 (24): 1942-1948.
  31. Rich-Edwards JW, Manson JE, Hennekens CH et al. The primary prevention of coronary heart disease in women. N Eng J Med 1995; 332: 1758-1766.
  32. Austoker J. Cancer prevention in primary care — current trends and some prospects for the future -1. BMJ 1994; 309: 449452.
  33. American Cancer Society. Summary of current guidelines for the cancer-related checkups recommentdation. New York, American cancer Society, 1988.
  34. Treizenberg DJ, Smith AM, Holmes TM. Cancer screening and detection in Family practice, a MIRNET Study. J Fam Pract 1995; 40: 27-33.
  35. Austoker J. Screening and self-examination for breast cancer. BMJ 1994; 309: 168-174.
  36. Jatoi I, Baum M. American and European recommendations for screening mammography in younger Women: a cultural divide. BMJ 1993; 307: 1481-83.
  37. Mcpherson K, Steel CM, Dixon JM, Breast cancer — epidemiology, risk factors, and genetic. BMJ 1994; 309: 1003-1006.
  38. Shapiro s, Venet N, Strax A et al. Ten to fourteen years effects of screening on breast. JNC 1 1982; 69: 349-355.
  39. Wright C J & Mueller C B. Screening mammography and public health policy: the need for prespective. Lancet 1995; 346: 29-32.
  40. Austoker J. Screening for colorectal cancer. BMJ 1994; 309: 382-386.
  41. Winawer SJ. et al. WHO guidelines for the prevention of colorectal cancer: update based on new data. WHO Collaborating Center for prevention of Cancer, 1994.
  42. Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371.
  43. Allison JE. Tekawa IS, Ranosom L J et al. A Comparison of fecal occult blood tests for colorectal cancer screening. N Eng J Med 1996; 334: 155-159.
  44. Austoker J. Melanoma: Prevention and early diagnosis. BMJ 1994; 308: 1682-1686.
  45. Menczer J. Case against cytological mass screening for cervical cancer in Israel. Harefuah 1992; 120: 802-804.
  46. Austoker J, Sanders D, Fowler G. Smoking and Cancer: Smoking cessation. BMJ 1994; 308: 1478-82.
  47. Blum A, Solberg E. The role of the family physician in ending the Tabacco pandemic. J Fam Pract 1992; 34 (6): 697-699.
  48. Kottke TE et al. A controlled trial to Integrate smoking cessation advice into primary care practice: Doctors helping smokers, Round III. J Fam Pract 1992; 34 (6): 701-708.
  49. Poshuma FM, Westendorp GJ, Vandenbroucke JP, Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1260-1270.
  50. American College of Physicians guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038-1041.
  51. Belchetz P. Hormonal treatment of postmenopausal women. N Eng J Med 1994; 330: 1062-64.
  52. Grady D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1038-1041.
  53. Riggs BA & Melton L J. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327 (9): 620-627.
  54. Colditz G A, Hankinson S E, Hunter D J et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995; 332: 1589-93.
  55. יתרונות וחסרונות הטיפול ההורמונלי התחליפי - עידכון. תרפיה שימושית בעריכת פהפ׳ רוזנפלד, ד״ר קיצס-כהן וד״ר גולדשמיד ־ אוקי 1994.
  56. Mead M. The over 75 Screening Card. Update 1991, May 987-994.
  57. When to use the new pneumococcal vaccine. Drugs Therap bull 1990 Apr 17: 28 (8): 31-32.
  58. Klinkman M S, Zazove P, Mehr DR & Ruffin MT. A Critierion-based review of priventive Health care in the elderly — Part 1. J Fam Pract 1992; 34: 205-22.
  59. Zazove P et al. Part 2 — A geriatric health maintenance program. J Fam pract 1992; 34: 320-347.
  60. Hepatitis B Virus. Recommendation of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40: 1-25.
  61. Expanded programme of Immunization Programme Report for the year 1992. World Health Organization, January 1993.
  62. Hollinger FB. Factors influencing the immune response to Hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendatgions. Amer J Med 1989; 87 (suppl 3A): 365405.
  63. Hali AJ. Hepatitis B vaccination: protection for how long and against what? BMJ 1993; 307: 276-7.
  64. Barshani S, Avitzur M, Tur-Kaspa R. Antibodies to hepatitis C in Israeli blood donors: age, sex and ethnic differences from HBsAg positive carriers, first Joint spanish-Israeli Meeting on Liver and Biliary Disease, jerusalem 1992.
  65. Green MS, Block C, Slater PE. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Reviews of Infectious Disease 1989; 11: 464-469.
  66. Bogomolski; Yahalom V, Granot N, Linder R, Korman S, Manny R, tur-Kaspa R, Shouval D. Prevalence of HBsAg carriers in native and immigrant pregnant female in Israel and passive/active vaccination against HBV of newborns at risk. J of Medical Virology 1991; 34: 217-222.
  67. Kramer BS, Brown ML, Prorok PC, Polosky AL, Gohagan JK. Prostate cancer screening what we know and what we need to know, ann Intern Med 1993; 119(9): 914-923.
  68. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen year survival in prostate cancer a prospective, Population based study in sweden. JAMA 1997; 277(6): 467-71.
  69. Walsh PC, Brooks JD. The Swedish Prostate cancer paradox. JAMA 1997; 277(6) 497-498.
  70. Screening Mammography in women younger than 50 years of Age. Ann of Intern Med 1995; 122: 550-52.
  71. Nystrom L, Rutqvist LE, Wall S et al. Breast cancer screening with mammography over view of Swedish randomised trials. The Lancet 1993; 334(8851): 973-978.
  72. Lynge E. Definition and Ongoing Programs. Nationl Board of Health screening, Copenhagen 1992.
  73. The Breast screening brawl. Science; 1997; 275: 1056-1059.
  74. Adami HO. Prostate Cancer Screening — overview Int J Cancer: Supple 9. 1996; 3-12 Publication of the international union against cancer.
  75. Cochrane AL, Holland WW. Validation of screening procedures. Brit Med Bull. 1971; 27: 3-8.
  76. Screening. British Medical Bulletin edited by Peckham C, Dezatevx C. Published by the Royal Saciety of Medicine London 1998; 54(4) 767-85.
  77. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA.1998; 280: 605-613.
  78. Sidney, Petitti & Ruesenberry. Kaiser case control Study. Ann Int Med 1997; 127: 501-8.
  79. EPI Primary Results Paper. JAMA 1995; 273(3): 199-208.
  80. Delmas P.O. Bjarnason NH, Mitlak BH et al. Effects of Raloxifene on Bone Mineral Density. Serum cholesterol concentrations and uterine endometrium in postmenopausal women. NEJM 1997; 337: 1641-1647.
  81. Grodstein F. Stampfer MS, Colditz GM et al. Postmenopausal hormone therapy and mortality. NEJM 1997: 336: (25) 1769-1775.
  82. Whitehead M. Treatment for menopausal and post menopausal problems: present and future. Balliere's clinical obstetrics and gynaecology. 1996: 10(3): 515-529.
  83. Barrett Connor E. Hormone replacement therapy BMJ; 1998; 317: 457-61.
  84. Lindsay R., Meunier P.J. Osteoporosis: Review of the evidence for prevention diagnosis and treatment and cost-effective analysis. Osteoporosis International: 1998; 8.
  85. Santoro N.F., Col N.F., Eckman M.H., Wong J.B., Pauker S.G., Cauley J.A., Zmuda J., Crawford S., Johannes C.B., Rossouw J.E., Merz C.N.B. Hormon Replaeement Therapy — Where are we going? JCEM 1999; 84; 6: 1798-1799.
  86. Osteoporosis — physicians guide to prevention and treatment of osteoporosis.
  87. Developed by the National Osteoporosis Foundation Washington 1997.
  88. Royal College of Physicians. Osteoporosis clinical guidelines for preventionnn and treatment, London: Royal College of Physicians, 1999.
  89. Battett-Connor E., Stuenkel C. Hormones and heart disease in women: Heart and estorgen/ progestin replacement study in perspective. JCEM 1999; 84; 6: 1848-9.
  90. Miller P.D., Zapalowski C, Kulak C.A.M., Bilezikian J.P. Bone densitometry: The best way to detect Osteoporosis and monitor therapy. JCEM 1999; 84; 6: 1867-8.
  91. Orwoll E.S., Nelson H.D. Does estrogen adequately protect postmenopausal women against osteoporosis: An inconoclastic perspective. JCEM 1999; 84; 6: 1872-3.
  92. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin interventions (PEPI) trial: The writingggg group for the PEPI. JAMA 1996; 276: 1389-1395.
  93. Michaelsson K, Baron JA, Farahmand, BY et al on behalf of the Swedish Hip Fracture Study Group. Hormone replacement therapy and risk of hip fracture: population based case control study. BMJ 1998; 316: 1858-1862.
  94. Santen J.R., Petroni G.R. Relative versus attributable risk of breast eancer from estorgen replacement therapay. JCEM 1999; 84; 6: 1875-6.
  95. Walsh B.W., The individualized approach to menopause management. JCEM 1999; 84; 6: 1900-1.
  96. Miettinen TA., Pyorala K., Olsson AG., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997; 96: 4211-4218.
  97. Lewis SJ., Sacks FM., Mitchell JS., et al. Effect of parvastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am College Cardiol. 1998; 32: 140-146.
  98. Downs JR., Clearfield M., Wies S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998; 279: 1615-622.
  99. Col NF., Eckman MH., Kara RH., et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997; 277: 1140-1147.
  100. Graday D., Rubin SM., Petitti DB., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117: 1016-1037.
  101. Nelson H., Harris E., Cauley J., et al. Osteoporosis and fracture are common in older postmenopausal women using estrogen. Bone. 1998; 23: S152.
  102. Bruce E., Dennis M.B., Bruce H.M., Ronald K.K., Thomas N., Harry K.G., Claus C, Pierr D.D., Jose RZ., Jacob S., Claus C.G., Dathrya K., Fredric J.C., Stephen E.,E., Louis V.A., Paul Lipa., Steven R.C. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. 1998, JAMA. 282; 637-645.
  103. Etinger B., Black DM., Mitlak BH., et al and the MORE investigators. Reduction of vertebral risk in post menopausal women with osteoporosis treated with raloxifen. JAMA 1999; 282(7): 637-645.
  104. Dawso-Hghs B., Harris SS., Krall EA., Dallal GE. Effect of calcium and Vit D suppplementation on bone density in men & women 65 years of age or alder. N Eng J Med 1997; 337: 670-676.
  105. Storm T., Thamsborg G., Genant HK., Sorenson OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N Eng J Med 1990; 333: 1437-1443.
  106. Van-Staa TP., Abenhaim L., Cooper C. Use of cyclical etidronate and prevention of non vertebral fractures. Br J Rheumatol 1998; 3777: 87-94.
  107. Liberman UA., Weiss SR., Broil J., Minne HW., Quan H., Bell NH., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Eng J Med 1995; 333: 1437-1443.
  108. Fogelman I. Screening for osteoporosis. BMJ 1999; 309: 114849.
  109. Lindsay R., Cosman F., Lobo RA., Walsh BW., et al. Addition of Alendronate to ongoing Hormone Replacement Therapy in the treatment of osteoporosis: A randomized controlled clinical trial. J Clin Endocrin Metab 1999; 84: 3076-81.
  110. המלצות הוועדה המדעית לחיסון ננגד דלקת נב1 נגיפית מסוג A, מתוך הנחיות קליניות - קווים מנחים, המלצות וניירות עמדה ברפואת המשפחה דו״ח הוועדה המקצועית מטעם האיגוד הישראלי לרפואת משפחה, ההסתדרות הרפואית בישראל, המועצה המדעית, האגף לאבטחת איכות והאגודה למלחמה בסרטן 1997 עמ׳ 76-71
  111. Furesz J, Scheifele D.W., Palkoyay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. Can. Med. Assoc J. 1995; 152 (3): 343-8.
  112. Leentvaa K.A., Coutinho R.A., Brulein V. Safary A. Simultneous passive and active immunization against hepatitis A. Vaccine. 1992; 10 suppl 1: 13841.
  113. The Journal of Infectious Diseases Vol. 171 Suppl 1 March 1995.
  114. Bruce L.I., Snitbhan R., Kunasol P. et al. Protection against Hepatitis inactivated vaccine. JAMA, 1994; 271: 1328-34.
  115. Horng Y.C., Chang M.H., Lee C.Y. et al Safety and immunogenicity of hepatitis A Vaccine in healthy children. Pediatr infect Dis J. 1993; 12: 359-62.
  116. Werzberger A., Mensch B., Kuter B. et al. A controlled trial of a formalin-inactivated hepatitis A Vaccine in healthy children. N. Engl J Med 1992; 327: 453-7.
  117. Bancrof W.H., Hepatitis A vaccine. N. Engl J. Ned. 1992; 327: 488-90.
  118. Tormans G., Van-Damme P., Van-Doorslaer E. Cost[effectiveness analysis of hepatitis A prevention in travellers. Vaccine. 1992 10 Suppl 1: 88-92.
  119. Van-Damme V., Cramm M., Van-der Auwera J., Meheus A. Hepatitis A Vaccintion in health care workers.
  120. Jilzey A.J., Palmer S.J., Barrow S. et al. Clinical trial with inactivated hepatitis A Vaccine and recommendations for its use. B.M. J. 1992; 304: 1272-76.
  121. Tilzey A.J., Banatvala J.E., Hepatitis A — changing prevalence and possible vaccines. B.M.J. 1991; 302: 1552-3.
  122. Prevention of Hepatitis A through active or passive immunization. Recommendations of the advisory commitee on immunization practices. U.S. Department of Health and Human Services. Center for Disease control and prevention 1995.
  123. Behrens R.H., Roberts J.A. Is travel prophylaxis worth while? Economic appraisal of profilactic measures against malaria, hepatitis A, and typhoid in travellers. B.M.J. 309: 918-22.
  124. Green M.S., Cohen D., Lerman Y., Sjogren M. et al. A trial of reactogenicity and immunogenicity of an inactivated heptitis A Vaccine, ISRAEL J. Med.Sci 1994; 30:485-88.
  125. Karetnyi Y. V., Mendelson E., Shlyakhov E, et al. Prevalence of antibodies against Hepatitis A virus ammong new immigrants in ISRAEL. J. Med. Virol 1995; 46: 61-65.
  126. Hepatitis A in ISRAEL — 1993. Monthly Epidemiological Record. Ministry of health, Department of Epidemiology ISRAEL. 1993.
  127. Bader T.F., Hepatitis A Vaccine. Am J. Gastroentero. 1996; 91(2): 217-22.
  128. Modan B., Shpilberg O., Sikuler E. et al. The need for liver transplantation: a nationwide estimate based on consesus review. Lancet. 1995: 346: 660-62.
  129. Ackerman Z., Ablin J, Shouval D. Active immunization against hepatitis A is now wannanted is G6PD deficient subjects. Am. J. Gastroenterol. 1996; 143.
  130. Krause D.S. Hepatitis A Vaxccines-letter to the editor. JAMA 1996; 276: 449450.
  131. Margolis H.S. Personal communication 1996.
  132. Adler R., Shouval D., Hepatitis A Prophylaxis. Vaccine or Immunoglobulin. Clin immunother 1996; 6(4): 261-272.
  133. Special report: Clinical preventive services: what's really worth doing for children from Contemporary Pediatrics. 1996; 13(3): 106-113.
  134. Bower C, Stanlly FJ. Issues in the prevention of spina bifida. J Royal society of Med. 1996; 89: 436-442.
  135. Laurence KM., James N., Miller MH., Tennant GB., Campbell H. Double blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural — tube defects. BMJ. 1981; 282: 1509-11.
  136. Bower C, Stanley FJ. Dietary Folate as a risk factor for neural tube defects: evidence from case — Control Study in Western — Australia. Med J of Australia. 1989; 150: 613-619.
  137. Milunsky A., Jick H., Jick S. et al. Multivitamin/Folic acid supplementation in early pregnancy reduces the prevalence of Neural Tube defects. JAMA 1989; 262(20): 2847-52.
  138. Swain RA., ST. Clair L. The role of Folic acid in deficiency States and prevention of disease J Fam Pract 1997; 44: 138-144.
  139. Law MR. Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315: 841-46.
  140. Philips A, Wannamethee SG, Walker M, et al. Life expectancy in men who have never smoked and those who have smoked continuously: 15 years follow-up of large cohort of middle aged British men BMJ 1996; 313: 907-8.
  141. סלע ב. המערכה מד עישון: האם אנו מתקרבים לרגע האמתל הרפואה 1996; כרך 131 עמ׳ 530-524.
  142. Hastings G, Macfadyen L, Stead M. Tabacco marketing: shacking the pied piper. BMJ 1997; 315: 43940.
  143. Davis RM. Passive smoking: history repeats itself. BMJ 1997; 315: 961-2.
  144. Hackshow AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tabacco smoke. BMJ 1997; 315: 980-88.
  145. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Enql J Med 1995; 332: 1758-66.
  146. Powell KE. Physical activity and health. BMJ 1996; 313: 126-7.
  147. Jones TF, Eaton CB. Exercise Prescription. Am Fam Physician 1995; 52: 543-553.
  148. Doll R, Peto R, Hall E, Weatley K, Gray R. Alcohol and Coronary heart disease reduction among British Doctors: Confounding and causality Eur. Heart J 1997; 18(1): 23-5.
  149. Shaper AG, Wannamethee G, Walker M. Alcohol and Coronary heart disease: a perspective from the British Regional Heart study. Int J Epidemiol 1994; 23(3): 482-94.
  150. Mcdonald P, Friedman EHI, Banks A, et al. Pneumococcal vaccine canpaign based in general practice BMJ 1997; 314: 1094-8.
  151. קופ״ח כללית ההנהלה המרכזית חוזר מרוכז 17/97 מיום 21.7.97 עמ׳ 10.
  152. Dowse GK, Gareeboo H, Alberti KG, et al. Changes in population cholesterol concerntrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention program in Mauritius. BMJ 1995; 311: 1255-59.
  153. ; 1998,48 יאיר יודפת. היפרליפידמיה - מה חדש ואיך נטפל. כתב העת הישראלי לרפואת משפחה כרך 8 11-4
  154. Israel J of - י. יודפת. מניעה בזיקנה - סקירה ראשית. כתב העת הישראלי לרפואת המשפחה פבר׳ 1996 כרך 26 עמי 10-4 .Family Practice
  155. Patterson CH, Feightner J. Promoting the health of senior citizens. Can Med Assoc J 1997; 157(8): 1107-13.
  156. Organizing committee of the Canadian consensus conference on the assessment of dementia. Can Med Assoc. J 1991; 144(7): 851-3.
  157. Goldberg TH, Chavin SI. Preventive medicine and screening in the older adults. JAGS. 1997; 45(3): 344-54.
  158. Feightner JW, Gass DA, Bass MJ. An approach to assessing dementia. Can Fam Physician. 1992; 38: 2347-53.
  159. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with Isolated systolic hypertention. JAMA 1991; 265: 3255-65.
  160. Joint National Committee on Detection, evaluation and treatment of high blood pressure. The sixth report of the National Committee on Detedion evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 24 Nov. 1997.
  161. Lever AF, Ramsey LE. Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571-9.
  162. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test — Hemoccult. BMJ 1998; 317: 559-65.
  163. Lahad A, Malter AD, Berg A, Deyo RA. The effectiveness of four interventions for the prevention of low back pain. JAMA 1994; 272: 1286-91.
  164. Daltroy LH; Iversen MD; Larson MG; et al. A controlled trial of an educational program to prevent low back injuries. N Engl J Med, 1997; 337: 322-8.
  165. Reddell CR, Congleton JJ, Huchingson RD, Montgomery JF. An evaluation of a weightlifting belt and back injury prevention training class for airline baggage handlers. Applied Ergonomics. 1992; 23: 319-329
  166. Cox JM, Trier KK. Exercise and smoking habits in patients with and without low back and leg pain. J Manipulative Physiol Ther. 1987; 10: 239-45.
  167. Battie MC, Videman T, Gill K, et al. Smoking and lumbar intervertebral disk degeneration: An MRI study of identical twins. Spine. 1991; 16: 1015-21.
  168. Holm S, Nachemson A. Nutrition of the intervertebral disc: acute effects of cigarette smoking. An experimental animal study. Ups J Med Sci. 1988; 93: 91-9.
  169. Gore DG, Passehl R, Sepic S, et al. Scoliosis screening: results of community project. Pediatrics 1981; 67: 196-200.
  170. Morais T, Bernier M, Turcotte F. Age and sex specific prevalence of scoliosis and the value of school programs. Am J Public Health 1985; 75: 1377-80.
  171. U.S. Preventive Services Task Force. Screening for adolescent idiopathic scoliosis: review article. JAMA 1993; 269: 2667-2672.
  172. Willers U, Normelli H, Aaro S, et al. Long-term results of Boston brace treatment on vertebral rotation in idiopathic scoliosis. Spine 1993; 18: 432-35.
  173. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90.
  174. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer. 1977; 20: 680-88.
  175. Friedman GD, Hiatt RA, Quesenberry CP, et al. Case-control study of screening for prostate cancer by digital rectal examination. Lancet 1991; 337: 1526-29.
  176. Gerber GS, Tompson IM, Thistad, et al. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA; 1993; 269: 61-64.
  177. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract. 1992; 34: 561-68.
  178. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analysis view. JAMA 1994; 272: 773-80.
  179. Cantor SB, Spann SJ, Volk RJ, et al. Prostate cancer screening: a decision analysis. J Fam Pract 1995; 41: 33-41.
  180. Beatt GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23: 414-20.
  181. Weiss W. Survivorship among men with bronchogenic carcinoma: three studies in populations screened every six months. Arch Environ Health 1971; 22: 168-73.
  182. Ebeling K, Nischan P. screening for lung cancer: results from a case-control study. Int J Cancer 1987; 40: 141-44.
  183. Kubik A, Parkin DM, Khlat M, et al. Lack of benefit from smi-annual screening for cancer of the lung: follow-up report of a randomized controlled trail on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
  184. Andolf E, Svalenius E, Astedt B. Ultrasonography for early detection of ovarian carcinoma. Br J Obstet Gynecol 1986; 93: 1286-89.
  185. Jacobs I. Screening for early ovarian cancer. Lancet 1988; 2: 171-172.
  186. Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988; 1: 268-271.
  187. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCAI and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. In press, Am J Human Genetics 1997; 60: 1059-67.
  188. Kemp HG, Kronmal RA, Vietstra RE, Frye FL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7: 479-83.
  189. Rose 6, Baxter PJ, Reid DD, MaCartney P. Prevalence and prognosis of electrocardio-graphic findings in middle-age men. Br Heart J 1978; 40: 636-43.
  190. Multiple Risk Factor Intervention Trail Reserch Group. Baseline electrocardiographic abnormalitis, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trail. Am J Cardiol 1985; 55: 1-15.
  191. Knutsen R, Knutsen SF, Curb JD, et al. The predictive value of resting electrocardiograms for 12 year incidence of coronary heart disease in Honolulu Heart Program. J Clin Epidemiol 1988; 41: 293-302.
  192. Weiner DA, Backer L, Bonow R. The diagnostic and prognostic significance of an asymptomatic positive exercise test Circulation 1987; 75: II-20-1.
  193. Josephson RA, shefrin E, Lakatta EG, et al. Can serial exercise testing improve prediction of coronary events in asymptomatic individual? Circulation 1990; 81: 20-4.
  194. McHenry PL, ODonnell J, Morris SN, Jordan JJ. The abnormal exercise electrocardiogram in apparently healthy man: a predictor of angina pectoris as an intial coronary event during long-term follow-up. Circulation 1984; 70: 547-51.
  195. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990; 81: 428-36.
  196. Epstein SE, Quyumi A, Bonow RO. Sudden cardiac death without warning: possible mechanisims and implications for screening asymptomatic populations. N Engl J Med 1989; 321: 320-23.
  197. Heering SL, Beller U, Baras M, et al. A cohort analysis of cervical cancer in Israeli jewish women. Gynecol Oncol, 1990; 39: 24448.
  198. Okamura K, Ueda K, Sone H, et al. A sensitive thyroid stimulation hormone assay for screening of thyroid function disorder in elderly Japanese. J Am Geriatr Soc 1989; 37: 317-322.
  199. Helfand M, Crapo LM. Screening for thyroid disease. Ann Inter Med 1990; 112: 840-49.
  200. De 10s Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specifisity, and cost-efFectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 1989; 149: 526-32.
  201. Franklyn JA. The management of hyperthyroidism!. N Engl J Med. 1994; 330: 1731-38.
  202. Fletcher S. Breast cancer Screening in women aged under 50. BMJ 1997; 314: 764-5.
  203. Tomati L, Aitio A, et al. Cancer: Causes, Occurrence and Control. International Agency for Research on Cancer Scientific Publications. No. 100. WHO, IARC, 1990; Lyon, France.
  204. Greenwald P, Kramer BS, Weed DL. Cancer Prevention and Control. Marcel Dekker Inc. 1995; New York, USA.
  205. Stoll B, Love SM. Reducing Breast Cancer Risk in Women. Kluwer Academic Publications 1995; Dordrecht, The Netherlands.
  206. Parkin DM, Muir CS. Cancer Incidence in Five Continents. International Agency for Research on Cancer Scientific Publications, 1992; Vol. VI. No. 120, WHO, IARC, Lyon, France.
  207. Kelsy JL, Hildreth NG. Breast and Gynecologic Cancer Epidemiology, CRC Press Inc. 1983; Boca Raton, Florida, U.S.A.
  208. Kelsy JL, Bernstein L. Epidemiology and Prevention of Breast Cancer. Annu Rev Public Health 1996;17:47-67.
  209. Rimm EB, Williams P, Fosher K et al Moderate alcohol intake and lower risk of coronary heart disease: Meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523-8.

תוספת ביבליוגרפיה למהדורת 2004

כללי

  1. U.S. Preventive Services Task Force Guide to Clinical Preventive Services, Third Edition: Periodic Updates. Vol. 1 - Methods and screening. Agency for health care research and quality, www.ahrq.gov, AHRQ Publication No 02-500 Sep 2002.
  2. U.S. preventive Services Task force Guide to Clinical preventive Services, Third Edition: Periodic Updates. Vol. 2 - Chemoprevention and counseling. HARQ, Publication No 02-500 Sep 2002.
  3. מגמות בתחלואה ובתמותה מסרטן בישראל. הוצאת האגודה למלחמה בסרטן והמרכז .211 הלאומי לבקרת מחלות, משרד הבריאות 1998.
  4. בריאות בישראל נתונים נבחרים. בעריכת אבורבה מ, עוזרי ר, גורדון ש, שטיין נ, מרציאנו א, חקלאי צ. משרד הבריאות מדינת ישראל 2001. ועדכון דו״ח הלשכה המרכזית לסטטיסטיקה לוחות 6.13,6.14.

ילדים ומתבגרים

  1. בריאות התלמיד מידע שימושי. בעריכת בארי קנישקווי, יונה אמיתי, מירה חונוביץ. משרד הבריאות, שירותי בריאות הציבור, המחלקה לאם, לילד ולמתבגר, הסיעוד בבריאות הציבור, המחלקה לחינוך לבריאות. הפקה שראל שמתים ואספקה רפואית בע״מ 2003.
  2. Weinstein SL, Lori A Dolan, Spratt KF. Health and function of patients with untreated idiopathic scoliosis. JAMA 2003; 289: 559-567.

אלימות במשפחה וכנגד נשים

  1. MacMiller HL, Wathen CN with the Canadian Task Force on Preventive Health Care. Prevention and treatment of violence against women - systematic review and recommenda¬tion. www.ctfphc.org/Tables/Domestic_Violence_tab.htm.
  2. Rhodes KV, Levinson W. Interventions for intimate partner violence against women. JAMA 2003; 289: 601-605.
  3. Wathen CN & MacMillan HL. Interventions for violence against women. JAMA 2003; 289: 589-600.
  4. Krug EG, Mercy JA, Dahlberg LL, Zwi AB. The world report on violence and health. Lancet 2002; 360: 1083-1088.
  5. אלימות בין בני זוג - עמדת ההסתדרות הרפואית בישראל והנחיות לרופאים בדבר זיהוי וטיפול - ההסתדרות הרפואית בישראל 2003.

איתור דיכאון

  1. Screening for depression: recommendations and Rationale - U.S. Preventive Task Force. Am Fam Phys 2002; 66(4): 647-650.
  2. Froom J. Sclager D. Stheker S, Jaff A. Detection of major depressive disorder in primary care patients. J Am Board Fam Pract 1993; 6: 5-11.

איתור סרטן העור

  1. Screening for skin cancer: Recommendation and rationale - U.S. Preventive services Task Force. Am Fam Phys 2002; 65(8): 1623-1626.
  2. Lamberg L. "Epidemic" of malignant Melanoma, True increase or better detection. JAMA 2002; 2879170; 2201

איתור מוקדם סרטן הריאה

  1. Mahadevial PJ, Fleisher LA, Frick KD Et al. Lung cancer screening with Helical Ccomputed Tomography in older adult smokers. JAMA 2003; 289(3): 313-322, 357-358.
  2. Swensen SJ. Screening for cancer with computed tomography. BMJ 2003; 326: 894-895.

איתור מוקדם של סרטן הערמונית

  1. Harris R, Lohr Kn Update of the U.S Preventive services Task Force on Screening for prostate cancer: recommendation and Rationale. Ann Intern Med 2002; 137: 917-929.
  2. Lu-Yao G, Albertsen PC, Stanfors JL et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seatle area and Connecticut. BMJ 2002; 325: 740-244, 725.
  3. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ; Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med. 2002; 347: 781-9.
  4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The Influence of Finasteride on the Development of Prostate Cancer. NEJM 2003; 349: 213-222.
  5. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361: 1122-1128.

איתור מוקדם של סרטן צוואר הרחם

  1. American cancer Society (ACS) Updates Guideline for the early detection of cervical neoplasia and cancer. Am Fam Physician 2003; 67(9): 2011-2016.
  2. Mohoney MC, Saslow D, Cohen CJ. ACS guideline for the early detection of cervical cancer. Am Fam Physician 2003; 67(8): 1677-1680.
  3. U.s Preventive Services Task Force. Screening for cervical cancer - recommendations and rationale. Am Fam Physician 2003; 67(8): 1759-1766.
  4. בורנשטיין י, אברמוביץ חץ חשיבות ביצוע סריקה המונית לגילוי מוקדם של סרטן צוואר הרחם במדינת ישראל. הרפואה 1992 כרך 122 חוב׳ יב׳, עמ׳ 180-176.

מניעת והפסקת עישון

  1. Jorenby D. Clinical efficacy of Buprpion in the management of smoking cessation. Drugs 2002; 62 suppl.2: 25-35.
  2. Rigotti NA. Treatment of tabacco use and dependence. N Eng J med 2002; 346(7): 506-512.
  3. www.nice.org.uk
  4. Guidance on the use of nicotine replacement therapy (NRT) and Bupropion for smoking cessation. Technology Appresial Guidenace - No 39 - Published by the National Institute for Clinical excellence (NICE) - March 2002.
  5. שטיינברג א, לוגר א, ממן ע, שטיינברג ש. השפעת העישון על מחלות אורתופדיות ותוצאות ניתוחים. הרפואה כרך 142 (ו): עמ׳ 445-442.
  6. Band PR, D Le N, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. The Lancet 2002; 360: 1044-1049,1033-1034.
  7. דו״ח שר הבריאות על העישון בישראל 2003-2002, סיוון התשס״ג, יוני 2003.
  8. National Cancer Institute: Changes in Cigarette-Related Risks and Their Implication for Prevention and Control. Smoking and Tobacco Control Monograph No. 8, USDHHS NIH NCL, (NIH) 1997, Publication 974213.
  9. ZS Benovitz. Drug Interactions With Tobacco Smoking: An Update. Clin Pharmacokinet 1999 36: 426.
  10. Burns DM. Nicotin Addiction. Harrison's Principles of Internal Medicine. 15th edition, pp 2574-2577.
  11. Fiore MC US public health service clinical practice guideline: treating tabacco use and dependence. Respir Care 2000; 45(10): 1200-1262.
  12. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tabacco use and dependence: an evidence-based clinical practice guideline for tabacco cessation. Chest 2002; 121(3): 686-687.
  13. Liberman DA, Prindiville S, Weiss DG. et al Risk Factors for advanced colonic neoplasia and hyperplastic polyps in symptomatic individuals. JAMA 2003; 290(22): 2959-67.

חיסון כנגד אבעבועות רוח

  1. Skull SA, Wang EEL with the Canadian Task Force on Preventive Health Care Preventive health care, 2001 update: Use of varicella in healthy population 1999.
  2. Prevention of Varicella, Update recommendations of the advisory committee on immunization practices. MMWR 1999; 48(6). U/S Department of Health and Human services.
  3. Varicella Vaccine update - Committee of infectious disease- American Academy of Pediatrics/
  4. Maharshak N, Somekh E. Hospitalization for varicella in center Israel. Accta Pediatr 1999; 88: 1-5.
  5. Tan AYS, Connett CJ, Connett GJ et al. Use of reformulated Oka strain varicella vaccine in healthy childern. Eur J Pediatrics 1996; 155: 706-11.
  6. Oxman MN. Immunization to reduce the frequency and sevirity of herpez zoster and its complications. Neurol 1995; 45(Suppl 8): S41-6.
  7. Gershon A, Silverstein S. Live attenuated varicella vaccine for prevention of Herpes zoster. Biologicals 1997; 25: 227-30.
  8. White CJ. Varicella Zoster virus vaccine. Clin Infec Dis 1997; 24: 753-63.

איתור מוקדם של סרטן המעי

  1. ח. סטרול, ר. אליקים, ז. הלפרין, נ. ארבר. מניעה וגילוי מוקדם של סרטן הכרכשת בכלל האוכלוסיה - יום עיון וסיכום עמדת האיגוד לגסטרואנטרולוגיה. הרפואה, 2003 כרך 142(3) עמ׳ 226-223.
  2. United States Preventive Services Task force Guidelines: screening for colorectal cancer recommendation and rationale. Prepared for the guide to clinical preventive services 3rd edition 2001, by Oragon health Sciences University, evidence Based Practice Center Portland Oregon. USPSTF Web site- www.preventiveservices.ahrq.gov.
  3. Walsh JME, Terdiman JP. Colorectal cancer screening. JAMA 2003; 289: 1288-1296.
  4. Sonnenberg A, Dele F. Cost effectiveness of single colonoscopy in screening for colorectal cancer. Arch Intern Med 2002; 162: 163-168.
  5. Preventive Health Care, 2001 update: Colorectal Cancer Screening. Prapered by McLeod R with the Canadian task force on Preventive health care. www.ctfphc.org/Tables/C010r-ectal_Ca_tab.htm.
  6. www.cmaj.ca/cgi/content/full
  7. Boyle P. Faecal occult blood testing (FOBT) as screening for colorectal cancer: The current controversy. Ann One 2002; 13(1): 16-18.
  8. Detsky AS. Screening for colon cancer - can we efford colonoscopy? N Eng J Med 2001; 345(8): 607-608.
  9. Imperiale TF, Wagner DR, Lin Ch Y et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Eng J Med 2002; 346: 1781-1785.
  10. Pickhard PJ, Choi R, Hwong I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Eng J M 2003; 349: 2191-2200.

פעילות גופנית, השמנת יתר, יתר לחץ דם, היפרכולסטרולמיה ומניעת מחלות לב

  1. Kraus WE et al Effects of the amount and intensity of exercise on plasma lipoproteins. N Eng J Med 2002; 347: 1483-1492.
  2. Tall AR. Exercise to reduce cardiovascular risk - How much is enough? N Eng J Med 2002; 347: 1522-1524.
  3. Fontaine KR, Redden DT, Wang Ch. Years of life lost due to obesity. JAMA 2003; 289: 187-193.
  4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity and mortality from cancer in a prospectively studies cohort of U.S. adults. N Eng J Med 2003; 348: 1625-1638.

פולגמן י וחב׳ הנחיות קליניות בנושא מניעה וטיפול בהשמנת יתר. בהוצאת ההסתדרות .270 הרפואית בישראל 2003.

  1. Eatabrooks PA, Glasgow RE, Dzewaltowski DA. Physical activity promotion through primary care. JAMA 2003; 289: 2913-2916.
  2. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2003; 361(9353): 257-258.
  3. Chobanian AV, Bakris GL, Black HR et al -and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.
  4. Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counseling patients on physical activity in general practice: cluster randomized controlled trial. BMJ 2003; 326: 793-796.
  5. מסמך עמדה בנושא פעילות גופנית במסגרת מניעתה הראשונית של מחלת הלב הכלילית. דו״ח הועדה מטעם החוג לשיקום חולי לב והאיגוד הקרדיולוגי בישראל. ההסתדרות הרפואית - המועצה המדעית 2001.
  6. Hermansen K, Dinesen B, Hoie LH et al. Effects of soy and other natural products on LDL: HDL ratio and other lipid parameters: a literature review. Adv Ther 2003; 20(1): 50-78.
  7. LaRosa JC. Understanding the risk of hypercholesterolemia. Cin Cardiol 2003; 26(1 supple 1): I 3-6.
  8. Shepherd J, Gaw A. West of Scotland Coronary Prevention Study Group. The Anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Med Princ Pract 2002; 11 Suppl 2: 17-30.
  9. Chobanian AV, Bakris GL, Black HR et al, The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289(19): 2560-2570.
  10. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J of Hypertension 2003; 21: 1011-1053.
  11. Downs JR., Clearfield M., Wies S., et al. 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279: 1615-622.
  12. Lewis SJ., Sacks FM., Mitchell JS., et al. 1998 Effect of pavastain on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Colleague Cardiol. 32: 140-146
  13. הנחיות והמלצות בנושא טיפול ומניעה של מחלת לב כלילית וטרשת עורקים - בעריכת חרץ ד. ורובנשטיין א. - ההסתדרות הרפואית בישראל והאגף לאבטחת איכות 1999. דף עמדה מטעם המועצה הלאומית למניעת מחלות לב בנושא מניעה ראשונית של מחלת .284 לב כלילית וכלי דם באוכלוסיה הבוגרת - יו״ר - פרופ׳ צבעוני. 2003.
  14. Prevention and control of non-communicable diseases. In: Fifty-fifth World Health Assembly, Geneva, 13-18 May 2002. Vol 1. Geneva, World Health Organization, 2002: 28-30.
  15. Pushka P. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bulletin of the World Health Organization, 1998; 76: 416-25.

תזונה נכונה

  1. World Cancer Research Fund. Food, nutrition and the prevention of cancer: a global perspetive. Washington DC, American Institute for Cancer Research, 1997.
  2. Stubbs J, Ferres S, Horgan G. Energy density of foods: effects on energy intake. Critical Reviews in Food Science and Nutrition, 2000; 40: 481-515.
  3. Rolls BJ, Bells EA. Dietary approaches to treatment of obesity. Medical Clinics of North America., 2000; 40: 401-18.
  4. Depres JP. Treatment of obesity: need to focus on high-risk abdominally obese patients. British Medical Journal 2002; 322: 716-20.
  5. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2002; 346: 393-403.
  6. Mann J. Dietary fibre and diabetes revisited. Eur J Clin Nutr 2000; 55: 919-21.
  7. Oomen CM et al. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 2001; 357: 746-51.
  8. Sacks FM et al. Effects on blood pressure of reduced dietary sodium and the Diertary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.
  9. Burr ML et al. Effectrs of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
  10. Smith-Warner SA et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. J Am Med Assoc 2001; 285: 769-76.
  11. Nitzan Kaluski D, Ophir E, Kachal J, Shamir R, Eidelman A, Amitai Y, Boujanover Y, Baram N, Hisdai N, Haviv A, Branski D. Nutritional guidelines for infants and toddlers. Ministry of Health, Israel 2001.
  12. Kaluski DN, Leventhal A., Averbuch Y, Rishpon S, Cohen-Dar M, Habib S, Bellmaker I, Rubin L, Rachmiel S, Amitai Y and Palti H.
  13. Five decades of trends in iron deficiency anemia in Israeli infants: implications for food fortification policy. Eur J Clin Nutr 2001; 55: 82-7.
  14. Kaluski DN Chinich A, Leventhal A, Ifrah A, Cohen-Mannheim I, Merom D, Green MS. Overweight, stature, and socioeconomic status among women-cause or effect: Israel National Women's Health Interview Survey, 1998. J Gend Specif med. 2001; 4: 18-22.
  15. Steptoe A, Perkins-Parras L. Behavioral counseling to increase consumption of fruit and vegetables in low income adults randomized trial. BMJ 2003; 326: 855-861.
  16. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360(9336): 861-868.

רפואת מטיילים וטיסה

  1. Fundamentals of Aerospace Medicine, Dehart RL and Davis JR editors, Lippincott Williams & Wilkins, Philadelphia, PA 2002 (see Chapter 11, Health Maintenance and Promotion, co-authored by the author of this chapter).
  2. Clinical Aviation Medicine, 3rd ed 2000, Rayman RB, Castle Connoly Graduate Medical Publishing, LLC New York, NY.
  3. Aerospace Medical Asssociation Medical Guidelines Task Force. Medical guidelines for airline travel, 2nd ed. Aviation Space & Environmental Medicine 2003; 74(S): 1-19.
  4. Zuckerman JN. Clinical Review-Recent developments: Travel Medicine. BMJ 2002; 325: 260-264.
  5. Herxheimer A, Waterhouse J.The prevention and treatment of jet lag. BMJ 2003; 326: 296-297.
  6. Bagshaw M. et al. Travellers Thrombosis: A Review of Deep Vein Thrombosis Associated with Travel. Aviat Space Envir Med 2001; 72: 848-51.
  7. Wenzel RP. Airline Travel and Infection. N Engl J Med; 334: 981-2.
  8. http: //www.iata.org/pressroom/iata_speaks/2003-05-06-01.htm
  9. Samel A, Wegmann HM. Bright light: A countermeasure for jet lag? Chronobiol Int 1997; 14: 173-183.

מניעת מחלות לב וסרטן באמצעות תרופות - אספירין, טמוקסיפן, ולוקסיפן

  1. Hyden M, Pignone M, Philips Ch, Mulrow C. Aspirin for the primary prevention of cardiovascular events. Ann Int Med 2002; 136(2): 161-172.
  2. Herbert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 2000; 160: 3123-3127.
  3. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85: 265-271.
  4. Baron JA, Cole BF, Sandler RS et al. A randomized trial of Aspirin to prevent colorectal adenomas. N Eng J Med 2003; 348: 891-899.
  5. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Eng J Med 2003; 348: 879-880.
  6. Barrett-Connor E, Grady D, Sashegyi A et al. raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002; 287(7): 847-857.
  7. Cummings SR, Eckert S, Krueger KA et al. The effect of Raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281(23): 2189-2197,2243
  8. Levine M, Moutquin JM, Walton R, Feightner J - Canadian Task Force. Chemoprevention of breast Cancer www.ctfphc.org/Tables_printable/Chemoprev_tab_p.htm
  9. Cauley JA , Norton L, Lippman ME et al For the MORE Investigators. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. BREAST Cancer Research and treatment 2001; 65: 125-134.
  10. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care 2002; 8(22 suppl): s691-700.
  11. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002; 17(5): 552-558.
  12. Sexton RC jr. Aspirin in cardiovascular disease. Tenn Med 2001; 94(6): 208-210.
  13. The ATBC Study Group. Incidence of cancer and mortality following alfa Tocopherol and b Carotene supplementation. JAMA 2003; 290: 476-485.

אוסטיאופורוזיס

  1. אוסטיאופורוזיס לאחר גיל המעבר - איבחון, מניעה וטיפול. דו״ח הועדה מטעם העמותה הישראלית לאוסטיאופורוזיס ומחלת עצם. בעריכת פולדש יוסף ובהוצאת ההסתדרות הרפואית בישראל 2002.
  2. Sarkar S, Mitlak BH, Wong M et al. Relationships between bone mineral density and incident of vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17:1-10.
  3. Delmas PD. Treatment of postmenopausal osteoporosis. The Lancet 2002; 359: 2018-2026.
  4. Riggs BL, Hartmann LC. Selective Estrogen Receptor Modulators _ Mechanisms of Action and Application to clinical practice. N Engl J Med 2003; 348: 618-629.
  5. Santoro N. F. ,Col N.F., Eckman M.H., Wong J.B., Pauker S.G., Cauley J.A., Zmuda J., Crawford S., Johannes C.B., Rossouw J.E., Merz C.N.B. Hormon Replacement Therapy -Where are we going? JCEM 1999; 84; 6: 1798-1799.
  6. Battett-Connor E., Stuenkel C. Hormones and heart disease in women: Heart and estorgen/progestin replacement study in perspective. JCEM 1999; 84; 6: 1848-9.
  7. Miller P.D., Zapalowski C, Kulak C.A.M., Bilezikian J.P. Bone densitometry: The best way to detect Osteoporosis and monitor therapy. JCEM 1999; 84; 6: 1867-8.
  8. Nelson HD, Harris E., Cauley J., et al. 1998 Osteoporosis and fracture are common in older postmenopausal women using estrogen. Bone. 23: SI52.
  9. Kleerekoper M. Lessons from the skeleton: was the Women's Health Initiative (WHI) a primary prevention trial? Osteoporos Int. 2002 Sep; 13(9): 685-7.
  10. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 Aug; 87(8): 3609-17.
  11. Siris E, Adachi JD, Lu Y, Fuerst T, Crans GG, Wong M, Harper KD, Genant HK. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int. 2002 Nov; 13(11): 907-13.
  12. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang 0, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 10; 344(19): 1434-41.
  13. Osteoporosis Prevention, Diagnosis and Therapy. NIH Consensus Statement Online. 2000; 17(1): 1-36. Available at: http//odp.od.nih.gov/consensus/cons/lll/lll_statement.htm. Accessed February 27, 2002.
  14. Screening for osteoporosis in postmenopausal women - U.S Preventive Services Task Forse. Third Edition: Periodic Updates Sep 2002 P 211-217.

ויטמינים למניעת מחלות

  1. Lebenthal E, Shapira N. Nutrition in the female life cycle. Published by ISAS International Seminar Ltd. Jerusalem & Danone Institute 2001.
  2. Willett WC, Stampfer MJ. What vitamins should I be taking, Doctor? NEJM 2001; 345: 1819-1824.
  3. Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention. JAMA 2002; 287: 3127-3129.
  4. Morris CD, Carson S. With the U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: Recommendations and rationale. Ann Intern. Med 2003; 139: 51-70.

טיפול הורמונלי בגיל המעבר

  1. פינס ע. טיפול הורמונלי חלופי בגיל חדילת אורח למניעת מחלות לב - החלום שנגוז? הרפואה כרך 142 (ג) עמ׳ 165-163.
  2. Mendelsohn ME & Karas RH, The protective effects of estrogen on the cardiovascular system. N Eng J Med 1999; 340: 1801-1811.
  3. Herrington DM, Reboussin KB, Brosnihan KB et al. effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Eng J Med 2000; 343: 522-529.
  4. Poulter N. Oestrogen and protection against cardiovascular disease: potential versus reality.Epidemiology 2001; 8(6): 383-390.
  5. Writing group for the Women's Health Initiative Investigators. Risks and benefits from the women's Health Initiative in healthy postmenopausal women. JAMA 2002; 288: 321-333.
  6. Stevenson JC & Whitehead IM. Hormone replacement therapy. Findings of Women's Health Initiative trial need not alarm users. BMJ, 2002; 325: 113-114.
  7. Chlebowski RT, hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women- The women's health initiative randomized trial. JAMA 2003; 289: 3243-3253.
  8. Li Ch.I, Malone KE, Porter PL et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254-3263.
  9. Gann PH & Morrow M. Combined hormone therapy and breast cancer - A single edged sword. JAMA 2003; 289: 3304-3308.
  10. מצב הבריאות בישראל, משרד הבריאות - המרכז הלאומי לבקרת מחלות 1997, פרסום 202 עמ׳ 65.
  11. Brewer D. What nonhormonal therapies are effective for postmenopausal vasomotor symptoms? J Fam Pract 2003; 52(4): 324-325.
  12. Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health related quality of life. N Engl J Med 2003; 348(19): 1839-54
  13. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322-326.
  14. Petitti DB, Hormone replacement therapy for prevention. JAMA 2002; 288(1): 99-101.
  15. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-368.
  16. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991 Sep 12; 325(11): 756-62
  17. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996 Aug 15; 335(7): 453-61
  18. Hulley S, et al. Randomized trail of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HERS JAMA 1998; 280: 605-13.
  19. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton LA, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
  20. Ross RK, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer: estrogen versus estrogen plus progestin. J Natl Cancer Inst.2000; 92: 328-332
  21. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734-741.
  22. Merom D, Ifrah A, et al. Factors predicting current use of hormone replacement therapy among menopausal Jewish women in Israel. IMAJ 2002; 4: 671-676.
  23. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy. JAMA 2002; 288: 872-81
  24. Sillero-Arenas M et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286-294.
  25. Colditz GA et al. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecal 1993; 168: 1473-80
  26. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
  27. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57
  28. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003; 289: 2673-84.
  29. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2663-72.
  30. Shumaker SA, Legault C, Thai L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2651-62
  31. Million women study collaboration. Breast cancer and hormone replacement therapy in the Million Women study. Lancet 2003; 362; 419-427.
  32. Blake JM, Collins JA, Reid RL, Fedorkow DM, Lalonde AB, Christilaw J, Fortier M, Fortin C, Jolly EE, Lemay A, O'Grady T, Smith TE, Cooper J, Maxted JM, O'Grady K, Turek MA; SOGC (Society of Obstetricians and Gynaecologists of Canada). The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can. 2002 Oct; 24(10): 783-90, 793-802.

איתור מוקדם של סרטן השד

  1. Miller AB, To T, Baines C, Wall C. Canadian National Breast Screening Study-2: 13 year results of a randomized trial in women aged 50-59 years. JNCI 2000; 92: 1490-1499.
  2. Ringash J. Canadian task force on preventive Health Care. Screening mammography among women aged 4049 years of age at average risk of breast cancer. CMAJ 2001; 164: 469476.
  3. Gotzsche PC, Olsen 0. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-134.
  4. Olsen 0, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-1342.
  5. EBCG editors, Cochrane Collaboration - Screening mammography: setting the record straight. Lancet 2002; 359: 439-440.
  6. Horton R. Screening mammography - an overview revisited. Lancet 2001; 358: 1284-1285.
  7. Miettinen OS, Henschke C, Pasmantier MW et al. mammographic screening; No reliable supporting evidence? Lancet 2002; 359: 404406.
  8. Correspondence - Update on effects of screening mammography. Lancet 2002; 360: 337-340.
  9. Tabar L, Yen MF, Vitak B et al. Mammography service screening and mortality in breast cancer patients: 20 year follow up before and after introduction of screening. Lancet 2003; 361(9367): 1405-1410.
  10. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 347-360, 363-365, 147.
  11. Screening for breast cancer: recommendation and rationale - U.S. preventive services task force. American family Physician 2002; 65(12): 2537-2544.
  12. Chemoprevention of Breast Cancer. Canadian Task Force recommendations www.ctfphc.org/references/chemoprev_bib.htm
  13. Rebbeck TR, Lynch HT, Neuhausen SL et al Prophylactic oophorectomy in carriers of BRCAI or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
  14. Prophylactic Bilateral mastectomy in carriers of BRCAI or BRCA2 mutations. N Engl J Med 2001
  15. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, Porter P, Hu YW, Zhao GL, Pan LD, Li W, Wu C, Coriaty Z, Evans I, Lin MG, Stalsberg H, Self SG. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002; 94: 1445-57.
  16. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 347-60.
  17. Gotzsche PC, Olsen 0. Is screening for breast cancer with mammography justifiable? Lancet. 2000; 355: 129-34.
  18. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists5 Collaborative Group. Lancet 1998; 351: 1451.
  19. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev 1993; 15: 157.
  20. אלוייס ת.מ, ניסן א, שפירא ר.מ. סקלייר־לוי מ, פרוינד ה, פרץ ת. ממוגרפיה סוקרת לאיבחון מוקדם של סרטן השד: העובדות, המחלוקות והיישום בישראל. הרפואה 2003, כרד 142 (ד) עמ׳ 286-281.

מניעה במבוגרים

  1. Preventive services for adults, Institute for clinical systems improvement (ICSI), Bloomington, Minnesota, March 2000.
  2. American college of Sports Medicine (ACSM) Position Stand - Exercise and physical activity for older adults. Medicine and Science in sports & exercise. Volume 29, no. 6 1998.
  3. Tinetti ME. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42-49.
  4. Feskanich D et al. Walking and leisure time activity and risk of hip fructure in postmenopausal women JAMA 2002; 288: 2300-2306.
  5. Heflin MT, Cohen HJ. Duke University. Cancer Screening in the Elderly/ www.hosp-pract.com/issues/2001/03/eldhef.htm
  6. גלינסקי וחב׳. מבחנים לאיתור זקנים בעלי סיכון גבוה לנפילות בקהילה ופרוטוקולים נלווים - מסקנות מפרוייקט למניעת נפילות קשישים בבאר שבע. הרפואה 2000 כרד 138(ג) עמ׳ 194-189.

מניעת מחלות כבד

  1. Clinical research workshop, The American Association for the study of Liver Diseases, Screening in Liver Disease.
  2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
  3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the united states. Hepatology 2002; 36: S74-S83.
  4. Center for disease control and prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(N0 RR-19); 1-39.
  5. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liv Dis 2003; 23: 39-46.
  6. Margolis HJ, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Sem Liv Dis 1991; 11: 84-92.
  7. Fattovich G. Natural history and prognosis of hepatitis B. Sem Liv Dis 2003; 23: 47-58.
  8. Marchesini G, Bugianesi E, Forlani G, Rizzetto m et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
  9. McLaren C, Barton J, Adams P, Harris E, Acton R, Press N et al. Hemochromatosis and iron overload screening (HEIRS) Study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003; 325: 53-62.

הסינדרום המטבולי

  1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Executive Summary NIH Publication No. 01-3670, May 2001.
  2. Ian Janssen; Peter T. Katzmarzyk; Robert Ross. Body Mass Index, Waist Circumference, and Health Risk: Evidence in Support of Current National Institutes of Health Guidelines. Arch Intern Med. 2002; 162: 2074-2079.
  3. Reaven GM. Banting Lecture. Role of Insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
  4. Reaven GM. Role of insulin resistance in human disease (syndrome x): an expanded definition. Annu Rev Med 1993; 44: 121
  5. Reaven et al. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Eng J Med 1996; 334: 374
  6. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002 Nov 19; 106(21): 2659-65.
  7. 204. Ridker PM et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med. 2002; 347: 1557.
  8. Rader DJ. Inflammatory markers of coronary risk. NEJM 2000; 343: 1179.
  9. Tall AR. Exercise to Reduce Cardiovascular Risk-How Much Is Enough? N Eng J Med 2002; 347: 1522
  10. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453.
  11. Tuomiletho J et al. The Finnish Diabetes Prevention Study Group. Prevention of type 2 Diabetes mellitus by changes UN lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001; 344: 1344.

יישום הנחיות רפואיות

  1. Solberg LI. Guideline Implementation: What the Literature Doesnt Tell Us. J Qual Improv 2000; 26: 525-36.
  2. Weingarten S. Using Practice Guideline Compendiums To Provide Better Preventive Care. Ann Int Med 1999; 454-8.
  3. Solberg LI, Kottke TE, Brekke ML. Will Primary care Clinics Organize Themselves to Improve the Delivery of Preventive Services? A Randomized Controlled Trial. Prev Med 1998; 27: 623-31.
  4. Gottlieb NH et al. The impact of Put Prevention into Practice on selected clinical preventive services in five Texas sites. Am J Prev Med 2001; 21: 35-40.
  5. Goodwin MA et al. A Clinical Trial of Tailored Office Systems for Preventive Service Delivery. The Study to Enhance Prevention by Understanding Practice (STEP-UP). Am J Prev Med 2001; 21: 20-28.
  6. Cornuz J et al. Physicians' attitudes towards prevention: importance of intervention-specific barriers and physicians' health habits. Fam Pract 2000; 17: 535-40.
  7. Hash RB, Munna RK, Vogel RL, Bason JJ. Does Physician Weight Affect Perception of Health Advice? Prev Med 2003; 36: 4144.
  8. Pal B. The doctor will text you now: is there a role for the mobile telephone in health care? BMJ 2003; 326; 607.